SA Asks: Which oncology companies are attractive M&A targets?
Source: SeekingAlpha
2025-05-30 15:00:49 ET
More on Gilead Sciences, Bristol-Myers Squibb Company , etc.
- Bristol-Myers Squibb: This Undervalued Dog Needs An Option Collar
- Bristol-Myers: Among The Cheapest Pharma Names, Now Yielding Above 5%
- Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence
- Global cancer drug sales growth to slow amid patent cliffs: report
- Autolus Therapeutics gets EU endorsement for leukemia treatment
Read the full article on Seeking Alpha
For further details see:
SA Asks: Which oncology companies are attractive M&A targets?
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
